Type: Prostate cancer
Professor Holst and Dr Centenera’s teams aim to develop a new drug treatment strategy to overcome resistance to hormone therapy in prostate cancer.
Alongside a clinical trial of ribociclib for prostate cancer, Professor Butler and her team will identify biomarkers that can be used to identify which patients this new drug is likely to benefit.
Cancer Council NSW researchers have found that over one third of long-term Australian prostate cancer survivors need more supportive care than they are getting.
This project will investigate how these vital pain suppressing neurons control pain in advanced breast and prostate cancer.
This project will advance the understanding of how prostate cancer progresses and could lead to a new much-needed diagnostic approach.
This project will focus on developing adaptive radiotherapy for locally advanced lung, prostate and oligometastatic cancer.
This project aims to show that certain nerve growth factors (proteins that stimulate the growth of nerves) are effective biomarkers for prostate cancer.
Associate Professor Holst’s team have been working on a new type of anti-cancer drug that can ‘starve’ prostate cancer cells and stop their growth.
This study found that a prostate cancer diagnosis puts Australian men at much higher risk of suicide compared to the general male population.
This project will lead to a clinical trial of a developed test to ensure the right patients receive and benefit from focal therapy for prostate cancer.